# Incidence of Major Cardiovascular Events in Diabetic Patients With ACS Undergoing Coronary Angioplasty and Treated With Clopidogrel 150 mg Versus 75 mg

Study · id `cardio:ct-nct03329261` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03329261](<https://clinicaltrials.gov/study/NCT03329261>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03329261

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Coronary and vascular disease; Diabetes and metabolic disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 167 participants.

## Technical summary

Registry record NCT03329261. Randomized; no masking; primary purpose treatment. Start 2017-12-07 (actual); primary completion 2019-03-24 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 167 participants (enrolled count; ClinicalTrials.gov record NCT03329261, source copy `cardio:ctgov-nct03329261-2019-12-23`, retrieved 2026-10-26)
- Started: 2017-12-07 (actual) (ClinicalTrials.gov record NCT03329261, source copy `cardio:ctgov-nct03329261-2019-12-23`, retrieved 2026-10-26)
- Primary completion: 2019-03-24 (actual) (ClinicalTrials.gov record NCT03329261, source copy `cardio:ctgov-nct03329261-2019-12-23`, retrieved 2026-10-26)
- Completion: 2019-12-20 (actual) (ClinicalTrials.gov record NCT03329261, source copy `cardio:ctgov-nct03329261-2019-12-23`, retrieved 2026-10-26)
- Countries: Tunisia (ClinicalTrials.gov record NCT03329261, source copy `cardio:ctgov-nct03329261-2019-12-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03329261-2019-12-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Incidence of Major Cardiovascular Events in Diabetic Patients With ACS Undergoing Coronary Angioplasty and Treated With Clopidogrel 150 mg Versus 75 mg
- Acronym: IDASCOP 1
- Condition: Diabetes Mellitus, Type 2
- Condition: NSTEMI - Non-ST Segment Elevation MI
- Condition: Coronary Angioplasty
- Intervention (Drug): Clopidogrel
- Lead sponsor: Laboratoires Teriak
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Non-ST-elevation heart attack (NSTEMI) (`cardio:nstemi`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry intervention is a member of this class by a sourced record link: P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)

## Provenance

Content hash: 39d85dc951a1744f757147561149800ed45d9652055615261262b3d656e2c7de
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
